Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid's innovative SiPore® technology. Read Full Article
Deciphex, a trailblazer in digital pathology solutions, is delighted to announce a successful €10m venture debt financing round. This strategic investment will fuel the company's capacity growth, headcount increase, service enhancement, and expansion to new markets, addressing the growing global demand in pathology services. Read Full Article
Cinclus Pharma Holding AB (publ) ("Cinclus Pharma"), a pharma company focused on the development of a novel treatment for gastroesophageal reflux disease ("GERD"), today announces that two abstracts from the company's phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD ("eGERD"), are being presented at the leading gastro conference United European Gastroenterology ("UEG") which is held in Copenhagen 14 – 17 October 2023. Read Press Release here
Sigrid Therapeutics has started the Shine clinical trial for SiPore21, a device designed to control diabetes and obesity. SiPore technology is based on mesoporous silica particles (MSPs), a colloidal amorphous silicon dioxide matrix. It acts like a “molecular sieve” to physically prevent the interaction between digestive enzymes and food, thereby reducing food breakdown into basic absorbable units. The SiPore21 device, if cleared, will be registered as a Class IIb medical device. Read Full Article
Company will also create 25 jobs this year Health insurer VHI has launched a new telehealth dermatology service in partnership with AllView Healthcare, (formerly DermView) saying it will provide rapid access to care and treatment for skin conditions including acne, lesions and melanomas Read Full Article in the Irish Times
